K27 Stock Overview
A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kodiak Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.20 |
| 52 Week High | US$6.83 |
| 52 Week Low | US$2.03 |
| Beta | 2.25 |
| 11 Month Change | 80.72% |
| 3 Month Change | 167.49% |
| 1 Year Change | 161.06% |
| 33 Year Change | -92.21% |
| 5 Year Change | n/a |
| Change since IPO | -86.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| K27 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 17.0% | -1.1% | 1.1% |
| 1Y | 161.1% | -18.8% | 7.2% |
Return vs Industry: K27 exceeded the German Biotechs industry which returned -18.3% over the past year.
Return vs Market: K27 exceeded the German Market which returned 8.6% over the past year.
Price Volatility
| K27 volatility | |
|---|---|
| K27 Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: K27's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: K27's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 108 | Victor Perlroth | kodiak.com |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company’s preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions.
Kodiak Sciences Inc. Fundamentals Summary
| K27 fundamental statistics | |
|---|---|
| Market cap | €325.98m |
| Earnings (TTM) | -€181.37m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs K27 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| K27 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$191.62m |
| Earnings | -US$191.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.65 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did K27 perform over the long term?
See historical performance and comparison